What You'll Learn
Table of Contents
How Common Is It?
Pooled trial data gives a firm number rather than an impression:
Pooling STEP 1–3 (semaglutide 2.4 mg, n=2,117; placebo, n=1,262), the most reported gastrointestinal events were nausea (43.9% vs 16.1%), diarrhoea (29.7% vs 15.9%), vomiting (24.5% vs 6.3%) and constipation (24.2% vs 11.1%). 99.5% of events were non-serious and 98.1% mild-to-moderate, occurring most often during or shortly after dose escalation.
PubMed PMID: 34514682 ↗Bottom line: 29.7% against 15.9% on placebo. Note how high the placebo figure is — a good share of what people attribute to the drug happens anyway during a period of changed eating.
Why The Same Drug Causes Both
People find it strange that one medication is blamed for constipation and diarrhoea at once. The mechanism explains it.
GLP-1 receptor agonists alter gut motility. Slowed gastric emptying is the headline effect and produces constipation. But motility changes are not uniform along the whole tract, and altered transit downstream affects how much water is absorbed from stool and how bile acids are handled.
Which direction an individual gets depends on their baseline transit, their diet, and where in dose escalation they are. Some people get both, alternating — which is disconcerting but not, in itself, alarming.
When It Happens
The pattern in the trial data is consistent: gastrointestinal effects cluster during and shortly after dose escalation, are overwhelmingly mild-to-moderate, and are transient.
That has a practical consequence. If diarrhoea arrives four days after a dose increase, it will most likely settle as you stabilise at that dose. If it arrives out of nowhere at a dose you have been on for months, it is less likely to be the medication and more likely to be something else — an infection, a food, another drug.
The Part That Actually Matters
Diarrhoea itself is unpleasant. Its consequences are what deserve attention, because fluid and electrolyte losses compound a problem that is already present on these medications.
Analysing FDA adverse-event reports, semaglutide showed the strongest acute kidney injury signal (PRR 1.25, 95% CI 1.08–1.44), above liraglutide (0.86) and tirzepatide (0.34). The authors identify the pathway plainly: volume depletion from severe nausea, vomiting and diarrhoea is the main cause of GLP-1-associated AKI. Disproportionality analysis shows reporting patterns, not incidence.
Full text on PMC ↗Bottom line: On a day with diarrhoea, fluid stops being a comfort issue. Water alone may not be enough — see the hydration guide for when electrolytes earn their place.
What Helps
- Replace fluid deliberately. Small amounts often, rather than large volumes that pass straight through.
- Ease off fat temporarily. Higher-fat meals worsen diarrhoea when bile-acid handling is disturbed. This is a short-term adjustment, not a permanent low-fat diet — some fat keeps the gallbladder emptying, which matters for other reasons.
- Keep protein up. Appetite drops further when the gut is unhappy, and protein is the first thing to slide.
- Note what preceded it. Sugar alcohols in protein bars and diet products cause diarrhoea in their own right, and intake of both tends to rise on these medications.
When To Stop Self-Managing
Most diarrhoea here is transient and manageable. These are not:
- Blood in the stool, or black tarry stool
- Fever alongside the diarrhoea
- Severe abdominal pain, particularly if constant rather than cramping
- Diarrhoea persisting beyond a few days, or preventing you keeping fluid down
- Signs of dehydration: much less urine, dizziness on standing, confusion
In 5,411 people prescribed a GLP-1 for weight loss, compared with bupropion–naltrexone, adjusted hazard ratios were 9.09 (95% CI 1.25–66.00) for pancreatitis, 4.22 (1.02–17.40) for bowel obstruction and 3.67 (1.15–11.90) for gastroparesis. Biliary disease was not significantly raised (1.50, 0.89–2.53). The intervals are wide because these events are rare.
PubMed PMID: 37796527 ↗Important: Severe abdominal pain is the symptom that changes the picture entirely. Pancreatitis and bowel obstruction are rare but documented in this drug class, and both present with pain rather than with ordinary bowel upset.
